Targeting histone deacetylases for the treatment of huntington's disease

CNS Neuroscience and Therapeutics

Volumn 16, Issue 6, 2010, Pages 348-361

  Gray, Steven G ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

Epigenetics; Histone deacetylase; Huntington's disease; Neuromuscular disease

Indexed keywords

4 PHENYLBUTYRIC ACID; BUTYRIC ACID; HISTONE DEACETYLASE; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; HISTONE LYSINE METHYLTRANSFERASE; HUNTINGTIN; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; RE1 SILENCING TRANSCRIPTION FACTOR; SEN 0014196; TRANSCRIPTION FACTOR; TUBULIN; UNCLASSIFIED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; VORINOSTAT;

ACETYLATION; DISEASE ASSOCIATION; DOWN REGULATION; DRUG SAFETY; DRUG TOLERABILITY; ENDOPLASMIC RETICULUM STRESS; GENE EXPRESSION; GENE MUTATION; HISTONE CODE; HUMAN; HUNTINGTON CHOREA; NONHUMAN; PALMITOYLATION; PROTEIN PHOSPHORYLATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SUMOYLATION; UBIQUITINATION;

ANIMALS; DISEASE MODELS, ANIMAL; ENDOPLASMIC RETICULUM; GENE EXPRESSION; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; HUNTINGTON DISEASE; UBIQUITIN;

EID: 78649292318     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2010.00184.x     Document Type: Review

References (152)

1. Walker FO,. Huntington's disease. Lancet 2007; 369: 218 - 228.
2. DiFiglia M, Sapp E, Chase K, et al,. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron 1995; 14: 1075 - 1081.
3. Group THsDCR. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72: 971 - 983.
4. Klement IA, Skinner PJ, Kaytor MD, et al., Ataxin-1 nuclear localization and aggregation: Role in polyglutamine-induced disease in SCA1 transgenic mice. Cell 1998; 95: 41 - 53.
5. Sieradzan KA, Mechan AO, Jones L, Wanker EE, Nukina N, Mann DM,. Huntington's disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein. Exp Neurol 1999; 156: 92 - 99.
6. Saudou F, Finkbeiner S, Devys D, Greenberg ME,. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 1998; 95: 55 - 66.
7. Kazantsev A, Preisinger E, Dranovsky A, Goldgaber D, Housman D,. Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian Cells. Proc Natl Acad Sci U S A 1999; 96: 11404 - 11409.
8. Steffan JS, Kazantsev A, Spasic-Boskovic O, et al,. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci U S A 2000; 97: 6763 - 6768.
9. Steffan JS, Bodai L, Pallos J, et al,. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 2001; 413: 739 - 743.
10. Nucifora FC, Jr,., Sasaki M, Peters MF, et al,. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 2001; 291: 2423 - 2428.
11. Boutell JM, Thomas P, Neal JW, et al,. Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin. Hum Mol Genet 1999; 8: 1647 - 1655.
12. Yohrling GJ, Farrell LA, Hollenberg AN, Cha JH,. Mutant huntingtin increases nuclear corepressor function and enhances ligand-dependent nuclear hormone receptor activation. Mol Cell Neurosci 2003; 23: 28 - 38.
13. Bates EA, Victor M, Jones AK, Shi Y, Hart AC,. Differential contributions of Caenorhabditis elegans histone deacetylases to huntingtin polyglutamine toxicity. J Neurosci 2006; 26: 2830 - 2838.
14. Hubbert C, Guardiola A, Shao R, et al,. HDAC6 is a microtubule-associated deacetylase. Nature 2002; 417: 455 - 458.
15. Muchowski PJ, Ning K, D'Souza-Schorey C, Fields S,. Requirement of an intact microtubule cytoskeleton for aggregation and inclusion body formation by a mutant huntingtin fragment. Proc Natl Acad Sci U S A 2002; 99: 727 - 732.
16. Hoffner G, Kahlem P, Djian P,. Perinuclear localization of huntingtin as a consequence of its binding to microtubules through an interaction with beta-tubulin: Relevance to Huntington's disease. J Cell Sci 2002; 115: 941 - 948.
17. Trushina E, Heldebrant MP, Perez-Terzic CM, et al,. Microtubule destabilization and nuclear entry are sequential steps leading to toxicity in Huntington's disease. Proc Natl Acad Sci U S A 2003; 100: 12171 - 12176.
18. Dompierre JP, Godin JD, Charrin BC, et al,. Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation. J Neurosci 2007; 27: 3571 - 3583.
19. Weydt P, Soyal SM, Gellera C, et al,. The gene coding for PGC-1alpha modifies age at onset in Huntington's Disease. Mol Neurodegener 2009; 4: 3.
20. Taherzadeh-Fard E, Saft C, Andrich J, Wieczorek S, Arning L,. PGC-1alpha as modifier of onset age in Huntington disease. Mol Neurodegener 2009; 4: 10.
21. Lawless MW, O'Byrne KJ, Gray SG,. Oxidative stress induced lung cancer and COPD: Opportunities for epigenetic therapy. J Cell Mol Med 2009; 13: 2800 - 2821.
22. Chaturvedi RK, Adhihetty P, Shukla S, et al,. Impaired PGC-1alpha function in muscle in Huntington's disease. Hum Mol Genet 2009; 18: 3048 - 3065.
23. Weydt P, Pineda VV, Torrence AE, et al,. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell Metab 2006; 4: 349 - 362.
24. Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D,. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 2006; 127: 59 - 69.
25. Ryu H, Lee J, Hagerty SW, et al,. ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease. Proc Natl Acad Sci U S A 2006; 103: 19176 - 19181.
26. Hublitz P, Albert M, Peters AH,. Mechanisms of transcriptional repression by histone lysine methylation. Int J Dev Biol 2009; 53: 335 - 354.
27. Wiencke JK, Zheng S, Morrison Z, Yeh RF,. Differentially expressed genes are marked by histone 3 lysine 9 trimethylation in human cancer cells. Oncogene 2008; 27: 2412 - 2421.
28. Lee J, Hagerty S, Cormier KA, et al,. Monoallele deletion of CBP leads to pericentromeric heterochromatin condensation through ESET expression and histone H3 (K9) methylation. Hum Mol Genet 2008; 17: 1774 - 1782.
29. Packer AN, Xing Y, Harper SQ, Jones L, Davidson BL,. The bifunctional microRNA miR-9/miR-9* regulates REST and CoREST and is downregulated in Huntington's disease. J Neurosci 2008; 28: 14341 - 14346.
30. Zuccato C, Tartari M, Crotti A, et al,. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet 2003; 35: 76 - 83.
31. Gray SG,. Histone deacetylase inhibitors as a therapeutic modality in multiple sclerosis. In:, Zouali M, editor. The epigenetics of autoimmune diseases. Chichester, West Sussex: Wiley-Blackwell, 2009; 403 - 432.
32. Wu J, Xie X,. Comparative sequence analysis reveals an intricate network among REST, CREB and miRNA in mediating neuronal gene expression. Genome Biol 2006; 7: R85.
33. Conaco C, Otto S, Han JJ, Mandel G,. Reciprocal actions of REST and a microRNA promote neuronal identity. Proc Natl Acad Sci U S A 2006; 103: 2422 - 2427.
34. Bithell A, Johnson R, Buckley NJ,. Transcriptional dysregulation of coding and non-coding genes in cellular models of Huntington's disease. Biochem Soc Trans 2009; 37: 1270 - 1275.
35. Jiang H, Nucifora FC, Jr,., Ross CA, DeFranco DB,. Cell death triggered by polyglutamine-expanded huntingtin in a neuronal cell line is associated with degradation of CREB-binding protein. Hum Mol Genet 2003; 12: 11 - 12.
36. Cong SY, Pepers BA, Evert BO, et al,. Mutant huntingtin represses CBP, but not p300, by binding and protein degradation. Mol Cell Neurosci 2005; 30: 560 - 571.
37. Jiang H, Poirier MA, Liang Y, et al,. Depletion of CBP is directly linked with cellular toxicity caused by mutant huntingtin. Neurobiol Dis 2006; 23: 543 - 551.
38. Borovecki F, Lovrecic L, Zhou J, et al,. Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. Proc Natl Acad Sci U S A 2005; 102: 11023 - 11028.
39. Hughes RE, Lo RS, Davis C, et al,. Altered transcription in yeast expressing expanded polyglutamine. Proc Natl Acad Sci U S A 2001; 98: 13201 - 13206.
40. Sadri-Vakili G, Bouzou B, Benn CL, et al,. Histones associated with downregulated genes are hypo-acetylated in Huntington's disease models. Hum Mol Genet 2007; 16: 1293 - 1306.
41. Stack EC, Del Signore SJ, Luthi-Carter R, et al,. Modulation of nucleosome dynamics in Huntington's disease. Hum Mol Genet 2007; 16: 1164 - 1175.
42. Zuccato C, Belyaev N, Conforti P, et al,. Widespread disruption of repressor element-1 silencing transcription factor/neuron-restrictive silencer factor occupancy at its target genes in Huntington's disease. J Neurosci 2007; 27: 6972 - 6983.
43. Roze E, Betuing S, Deyts C, et al,. Mitogen- and stress-activated protein kinase-1 deficiency is involved in expanded-huntingtin-induced transcriptional dysregulation and striatal death. Faseb J 2008; 22: 1083 - 1093.
44. Kim MO, Chawla P, Overland RP, Xia E, Sadri-Vakili G, Cha JH,. Altered histone monoubiquitylation mediated by mutant huntingtin induces transcriptional dysregulation. J Neurosci 2008; 28: 3947 - 3957.
45. Wyce A, Xiao T, Whelan KA, et al,. H2B ubiquitylation acts as a barrier to Ctk1 nucleosomal recruitment prior to removal by Ubp8 within a SAGA-related complex. Mol Cell 2007; 27: 275 - 288.
46. Morris SA, Shibata Y, Noma K, et al,. Histone H3 K36 methylation is associated with transcription elongation in Schizosaccharomyces pombe. Eukaryot Cell 2005; 4: 1446 - 1454.
47. Schaft D, Roguev A, Kotovic KM, et al,. The histone 3 lysine 36 methyltransferase, SET2, is involved in transcriptional elongation. Nucleic Acids Res 2003; 31: 2475 - 2482.
48. Xiao T, Hall H, Kizer KO, et al,. Phosphorylation of RNA polymerase II CTD regulates H3 methylation in yeast. Genes Dev 2003; 17: 654 - 663.
49. Li B, Howe L, Anderson S, Yates JR, 3rd, Workman JL,. The Set2 histone methyltransferase functions through the phosphorylated carboxyl-terminal domain of RNA polymerase II. J Biol Chem 2003; 278: 8897 - 8903.
50. Krogan NJ, Kim M, Tong A, et al,. Methylation of histone H3 by Set2 in Saccharomyces cerevisiae is linked to transcriptional elongation by RNA polymerase II. Mol Cell Biol 2003; 23: 4207 - 4218.
51. Lee JS, Shilatifard A,. A site to remember: H3K36 methylation a mark for histone deacetylation. Mutat Res 2007; 618: 130 - 134.
52. Keogh MC, Kurdistani SK, Morris SA, et al,. Cotranscriptional set2 methylation of histone H3 lysine 36 recruits a repressive Rpd3 complex. Cell 2005; 123: 593 - 605.
53. Sun XJ, Wei J, Wu XY, et al,. Identification and characterization of a novel human histone H3 lysine 36-specific methyltransferase. J Biol Chem 2005; 280: 35261 - 35271.
54. Bres V, Yoh SM, Jones KA,. The multi-tasking P-TEFb complex. Curr Opin Cell Biol 2008; 20: 334 - 340.
55. Fu J, Yoon HG, Qin J, Wong J,. Regulation of P-TEFb elongation complex activity by CDK9 acetylation. Mol Cell Biol 2007; 27: 4641 - 4651.
56. Xu WS, Parmigiani RB, Marks PA,. Histone deacetylase inhibitors: Molecular mechanisms of action. Oncogene 2007; 26: 5541 - 5552.
57. Warby SC, Doty CN, Graham RK, Shively J, Singaraja RR, Hayden MR,. Phosphorylation of huntingtin reduces the accumulation of its nuclear fragments. Mol Cell Neurosci 2009; 40: 121 - 127.
58. Luo S, Vacher C, Davies JE, Rubinsztein DC,. Cdk5 phosphorylation of huntingtin reduces its cleavage by caspases: Implications for mutant huntingtin toxicity. J Cell Biol 2005; 169: 647 - 656.
59. Zala D, Colin E, Rangone H, Liot G, Humbert S, Saudou F,. Phosphorylation of mutant huntingtin at S421 restores anterograde and retrograde transport in neurons. Hum Mol Genet 2008; 17: 3837 - 3846.
60. Colin E, Zala D, Liot G, et al,. Huntingtin phosphorylation acts as a molecular switch for anterograde/retrograde transport in neurons. Embo J 2008; 27: 2124 - 2134.
61. Anne SL, Saudou F, Humbert S,. Phosphorylation of huntingtin by cyclin-dependent kinase 5 is induced by DNA damage and regulates wild-type and mutant huntingtin toxicity in neurons. J Neurosci 2007; 27: 7318 - 7328.
62. Thompson LM, Aiken CT, Kaltenbach LS, et al,. IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. J Cell Biol 2009; 187: 1083 - 1099.
63. Jeong H, Then F, Melia TJ, Jr,., et al. Acetylation targets mutant huntingtin to autophagosomes for degradation. Cell 2009; 137: 60 - 72.
64. Maynard CJ, Bottcher C, Ortega Z, et al,. Accumulation of ubiquitin conjugates in a polyglutamine disease model occurs without global ubiquitin/proteasome system impairment. Proc Natl Acad Sci U S A 2009; 106: 13986 - 13991.
65. Wang J, Wang CE, Orr A, Tydlacka S, Li SH, Li XJ,. Impaired ubiquitin-proteasome system activity in the synapses of Huntington's disease mice. J Cell Biol 2008; 180: 1177 - 1189.
66. Bennett EJ, Shaler TA, Woodman B, et al,. Global changes to the ubiquitin system in Huntington's disease. Nature 2007; 448: 704 - 708.
67. Steffan JS, Agrawal N, Pallos J, et al,. SUMO modification of Huntingtin and Huntington's disease pathology. Science 2004; 304: 100 - 104.
68. Subramaniam S, Sixt KM, Barrow R, Snyder SH,. Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity. Science 2009; 324: 1327 - 1330.
69. Khoshnan A, Ko J, Watkin EE, Paige LA, Reinhart PH, Patterson PH,. Activation of the IkappaB kinase complex and nuclear factor-kappaB contributes to mutant huntingtin neurotoxicity. J Neurosci 2004; 24: 7999 - 8008.
70. Khoshnan A, Ko J, Tescu S, Brundin P, Patterson PH,. IKKalpha and IKKbeta regulation of DNA damage-induced cleavage of huntingtin. PLoS One 2009; 4: e5768.
71. Rutkowski DT, Kaufman RJ,. A trip to the ER: Coping with stress. Trends Cell Biol 2004; 14: 20 - 28.
72. Hebert DN, Molinari M,. In and out of the ER: Protein folding, quality control, degradation, and related human diseases. Physiol Rev 2007; 87: 1377 - 1408.
73. Rapoport TA,. Protein translocation across the eukaryotic endoplasmic reticulum and bacterial plasma membranes. Nature 2007; 450: 663 - 669.
74. Lai E, Teodoro T, Volchuk A,. Endoplasmic reticulum stress: Signaling the unfolded protein response. Physiology (Bethesda) 2007; 22: 193 - 201.
75. Caruso ME, Chevet E,. Systems biology of the endoplasmic reticulum stress response. Subcell Biochem 2007; 43: 277 - 98.
76. Ron D, Walter P,. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 2007; 8: 519 - 529.
77. Pahl HL, Baeuerle PA,. The ER-overload response: Activation of NF-kappa B. Trends Biochem Sci 1997; 22: 63 - 67.
78. Xu C, Bailly-Maitre B, Reed JC,. Endoplasmic reticulum stress: Cell life and death decisions. J Clin Invest 2005; 115: 2656 - 2664.
79. Vembar SS, Brodsky JL,. One step at a time: Endoplasmic reticulum-associated degradation. Nat Rev Mol Cell Biol 2008; 9: 944 - 957.
80. Rao RV, Ellerby HM, Bredesen DE,. Coupling endoplasmic reticulum stress to the cell death program. Cell Death Differ 2004; 11: 372 - 380.
81. Waelter S, Boeddrich A, Lurz R, et al,. Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. Mol Biol Cell 2001; 12: 1393 - 1407.
82. Reijonen S, Putkonen N, Norremolle A, Lindholm D, Korhonen L,. Inhibition of endoplasmic reticulum stress counteracts neuronal cell death and protein aggregation caused by N-terminal mutant huntingtin proteins. Exp Cell Res 2008; 314: 950 - 960.
83. Atwal RS, Truant R,. A stress sensitive ER membrane-association domain in Huntingtin protein defines a potential role for Huntingtin in the regulation of autophagy. Autophagy 2008; 4: 91 - 93.
84. Atwal RS, Xia J, Pinchev D, Taylor J, Epand RM, Truant R,. Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity. Hum Mol Genet 2007; 16: 2600 - 2615.
85. Yang H, Liu C, Zhong Y, Luo S, Monteiro MJ, Fang S,. Huntingtin interacts with the cue domain of gp78 and inhibits gp78 binding to ubiquitin and p97/VCP. PLoS One 2010; 5: e8905.
86. Carra S, Sivilotti M, Chavez Zobel AT, Lambert H, Landry J,. HspB8, a small heat shock protein mutated in human neuromuscular disorders, has in vivo chaperone activity in cultured cells. Hum Mol Genet 2005; 14: 1659 - 1669.
87. Carra S, Seguin SJ, Landry J,. HspB8 and Bag3: A new chaperone complex targeting misfolded proteins to macroautophagy. Autophagy 2008; 4: 237 - 239.
88. Carra S, Seguin SJ, Lambert H, Landry J,. HspB8 chaperone activity toward poly(Q)-containing proteins depends on its association with Bag3, a stimulator of macroautophagy. J Biol Chem 2008; 283: 1437 - 1444.
89. Carra S, Brunsting JF, Lambert H, Landry J, Kampinga HH,. HspB8 participates in protein quality control by a non-chaperone-like mechanism that requires eIF2{alpha} phosphorylation. J Biol Chem 2009; 284: 5523 - 5532.
90. Noh JY, Lee H, Song S, et al,. SCAMP5 links endoplasmic reticulum stress to the accumulation of expanded polyglutamine protein aggregates via endocytosis inhibition. J Biol Chem 2009; 284: 11318 - 11325.
91. Carnemolla A, Fossale E, Agostoni E, et al,. Rrs1 is involved in endoplasmic reticulum stress response in Huntington disease. J Biol Chem 2009; 284: 18167 - 18173.
92. Fossale E, Wheeler VC, Vrbanac V, et al,. Identification of a presymptomatic molecular phenotype in Hdh CAG knock-in mice. Hum Mol Genet 2002; 11: 2233 - 2241.
93. Bardag-Gorce F, Dedes J, French BA, Oliva JV, Li J, French SW,. Mallory body formation is associated with epigenetic phenotypic change in hepatocytes in vivo. Exp Mol Pathol 2007; 83: 160 - 168.
94. Hanada S, Harada M, Kumemura H, et al,. Oxidative stress induces the endoplasmic reticulum stress and facilitates inclusion formation in cultured cells. J Hepatol 2007; 47: 93 - 102.
95. Ohoka N, Hattori T, Kitagawa M, Onozaki K, Hayashi H,. Critical and Functional Regulation of CHOP (C/EBP Homologous Protein) through the N-terminal Portion. J Biol Chem 2007; 282: 35687 - 35694.
96. Donati G, Imbriano C, Mantovani R,. Dynamic recruitment of transcription factors and epigenetic changes on the ER stress response gene promoters. Nucleic Acids Res 2006; 34: 3116 - 3127.
97. Baumeister P, Luo S, Skarnes WC, et al,. Endoplasmic reticulum stress induction of the Grp78/BiP promoter: Activating mechanisms mediated by YY1 and its interactive chromatin modifiers. Mol Cell Biol 2005; 25: 4529 - 4540.
98. Cherasse Y, Chaveroux C, Jousse C, et al,. Role of the repressor JDP2 in the amino acid-regulated transcription of CHOP. FEBS Lett 2008; 582: 1537 - 1541.
99. Doody GM, Stephenson S, Tooze RM,. BLIMP-1 is a target of cellular stress and downstream of the unfolded protein response. Eur J Immunol 2006; 36: 1572 - 1582.
100. Yu J, Angelin-Duclos C, Greenwood J, Liao J, Calame K,. Transcriptional repression by blimp-1 (PRDI-BF1) involves recruitment of histone deacetylase. Mol Cell Biol 2000; 20: 2592 - 2603.
101. Menendez-Benito V, Verhoef LG, Masucci MG, Dantuma NP,. Endoplasmic reticulum stress compromises the ubiquitin-proteasome system. Hum Mol Genet 2005; 14: 2787 - 2799.
102. Pandey UB, Nie Z, Batlevi Y, et al,. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 2007; 447: 859 - 863.
103. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP,. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 2003; 115: 727 - 738.
104. Boyault C, Zhang Y, Fritah S, et al,. HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates. Genes Dev 2007; 21: 2172 - 2181.
105. Kwon S, Zhang Y, Matthias P,. The deacetylase HDAC6 is a novel critical component of stress granules involved in the stress response. Genes Dev 2007; 21: 3381 - 3394.
106. Matthias P, Yoshida M, Khochbin S,. HDAC6 a new cellular stress surveillance factor. Cell Cycle 2008; 7: 7 - 10.
107. Wang JF, Bown C, Young LT,. Differential display PCR reveals novel targets for the mood-stabilizing drug valproate including the molecular chaperone GRP78. Mol Pharmacol 1999; 55: 521 - 527.
108. Bown CD, Wang JF, Young LT,. Increased expression of endoplasmic reticulum stress proteins following chronic valproate treatment of rat C6 glioma cells. Neuropharmacology 2000; 39: 2162 - 2169.
109. Chen B, Wang JF, Young LT,. Chronic valproate treatment increases expression of endoplasmic reticulum stress proteins in the rat cerebral cortex and hippocampus. Biol Psychiatry 2000; 48: 658 - 664.
110. Shao L, Sun X, Xu L, Young LT, Wang JF,. Mood stabilizing drug lithium increases expression of endoplasmic reticulum stress proteins in primary cultured rat cerebral cortical cells. Life Sci 2006; 78: 1317 - 1323.
111. Wang JF, Azzam JE, Young LT,. Valproate inhibits oxidative damage to lipid and protein in primary cultured rat cerebrocortical cells. Neuroscience 2003; 116: 485 - 489.
112. Shao L, Young LT, Wang JF,. Chronic treatment with mood stabilizers lithium and valproate prevents excitotoxicity by inhibiting oxidative stress in rat cerebral cortical cells. Biol Psychiatry 2005; 58: 879 - 884.
113. Cui J, Shao L, Young LT, Wang JF,. Role of glutathione in neuroprotective effects of mood stabilizing drugs lithium and valproate. Neuroscience 2007; 144: 1447 - 1453.
114. Qi X, Hosoi T, Okuma Y, Kaneko M, Nomura Y,. Sodium 4-phenylbutyrate protects against cerebral ischemic injury. Mol Pharmacol 2004; 66: 899 - 908.
115. Vilatoba M, Eckstein C, Bilbao G, et al,. Sodium 4-phenylbutyrate protects against liver ischemia reperfusion injury by inhibition of endoplasmic reticulum-stress mediated apoptosis. Surgery 2005; 138: 342 - 351.
116. Mulhern ML, Madson CJ, Kador PF, Randazzo J, Shinohara T,. Cellular osmolytes reduce lens epithelial cell death and alleviate cataract formation in galactosemic rats. Mol Vis 2007; 13: 1397 - 1405.
117. Bonapace G, Waheed A, Shah GN, Sly WS,. Chemical chaperones protect from effects of apoptosis-inducing mutation in carbonic anhydrase IV identified in retinitis pigmentosa 17. Proc Natl Acad Sci U S A 2004; 101: 12300 - 12305. (Pubitemid 39145438)
118. Yam GH, Gaplovska-Kysela K, Zuber C, Roth J,. Sodium 4-phenylbutyrate acts as a chemical chaperone on misfolded myocilin to rescue cells from endoplasmic reticulum stress and apoptosis. Invest Ophthalmol Vis Sci 2007; 48: 1683 - 1690.
119. Vij N, Fang S, Zeitlin PL,. Selective inhibition of endoplasmic reticulum-associated degradation rescues DeltaF508-cystic fibrosis transmembrane regulator and suppresses interleukin-8 levels: Therapeutic implications. J Biol Chem 2006; 281: 17369 - 17378.
120. Ozcan U, Yilmaz E, Ozcan L, et al,. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 2006; 313: 1137 - 1140.
121. Burrows JA, Willis LK, Perlmutter DH,. Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency. Proc Natl Acad Sci U S A 2000; 97: 1796 - 1801.
122. Kubota K, Niinuma Y, Kaneko M, et al,. Suppressive effects of 4-phenylbutyrate on the aggregation of Pael receptors and endoplasmic reticulum stress. J Neurochem 2006; 97: 1259 - 1268.
123. De Almeida SF, Picarote G, Fleming JV, Carmo-Fonseca M, Azevedo JE, De Sousa M,. Chemical chaperones reduce endoplasmic reticulum stress and prevent mutant HFE aggregate formation. J Biol Chem 2007; 282: 27905 - 27912.
124. Kegel KB, Meloni AR, Yi Y, et al,. Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription. J Biol Chem 2002; 277: 7466 - 7476.
125. Ferrante RJ, Kubilus JK, Lee J, et al,. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci 2003; 23: 9418 - 9427.
126. Gardian G, Browne SE, Choi DK, et al,. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J Biol Chem 2005; 280: 556 - 563.
127. Hockly E, Richon VM, Woodman B, et al,. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci U S A 2003; 100: 2041 - 2016.
128. Ebbel EN, Leymarie N, Schiavo S, et al,. Identification of Phenylbutyrate-Generated Metabolites in Huntington Disease Patients using Parallel LC/EC-array/MS and Off-line Tandem MS. Anal Biochem 2010; 399: 152 - 161.
129. Bachman DS, Butler IJ, McKhann GM,. Long-term treatment of juvenile Huntington's chorea with dipropylacetic acid. Neurology 1977; 27: 193 - 197.
130. Pearce I, Heathfield KW, Pearce MJ,. Valproate sodium in Huntington chorea. Arch Neurol 1977; 34: 308 - 309.
131. Symington GR, Leonard DP, Shannon PJ, Vajda FJ,. Sodium valproate in Huntington's disease. Am J Psychiatry 1978; 135: 352 - 354.
132. Saft C, Lauter T, Kraus PH, Przuntek H, Andrich JE,. Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's Disease patients: A case series. BMC Neurol 2006; 6: 11.
133. Grove VE, Jr,., Quintanilla J, DeVaney GT,. Improvement of Huntington's disease with olanzapine and valproate. N Engl J Med 2000; 343: 973 - 974.
134. Zadori D, Geisz A, Vamos E, Vecsei L, Klivenyi P,. Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease. Pharmacol Biochem Behav 2009; 94: 148 - 153.
135. Salazar Z, Tschopp L, Calandra C, Micheli F,. Pisa syndrome and parkinsonism secondary to valproic acid in Huntington's disease. Mov Disord 2008; 23: 2430 - 2431.
136. Thomas EA, Coppola G, Desplats PA, et al,. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc Natl Acad Sci U S A 2008; 105: 15564 - 15569.
137. Khan N, Jeffers M, Kumar S, et al,. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 2008; 409: 581 - 589.
138. Dokmanovic M, Perez G, Xu W, et al,. Histone deacetylase inhibitors selectively suppress expression of HDAC7. Mol Cancer Ther 2007; 6: 2525 - 2534.
139. Benn CL, Butler R, Mariner L, et al,. Genetic knock-down of HDAC7 does not ameliorate disease pathogenesis in the R6/2 mouse model of Huntington's disease. PLoS One 2009; 4: e5747.
140. Perez M, Santa-Maria I, Gomez De, Barreda E, et al,. Tau-an inhibitor of deacetylase HDAC6 function. J Neurochem 2009; 109: 1756 - 1766.
141. Jiang Q, Ren Y, Feng J,. Direct binding with histone deacetylase 6 mediates the reversible recruitment of parkin to the centrosome. J Neurosci 2008; 28: 12993 - 13002.
142. Aiken CT, Steffan JS, Guerrero CM, et al,. Phosphorylation of threonine 3: Implications for Huntingtin aggregation and neurotoxicity. J Biol Chem 2009; 284: 29427 - 29436.
143. Dephoure N, Zhou C, Villen J, et al,. A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 2008; 105: 10762 - 10767.
144. Pardo R, Colin E, Regulier E, et al,. Inhibition of calcineurin by FK506 protects against polyglutamine-huntingtin toxicity through an increase of huntingtin phosphorylation at S421. J Neurosci 2006; 26: 1635 - 1645.
145. Rangone H, Poizat G, Troncoso J, et al,. The serum- and glucocorticoid-induced kinase SGK inhibits mutant huntingtin-induced toxicity by phosphorylating serine 421 of huntingtin. Eur J Neurosci 2004; 19: 273 - 279.
146. Humbert S, Bryson EA, Cordelieres FP, et al,. The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev Cell 2002; 2: 831 - 837.
147. Schilling B, Gafni J, Torcassi C, et al,. Huntingtin phosphorylation sites mapped by mass spectrometry. Modulation of cleavage and toxicity. J Biol Chem 2006; 281: 23686 - 23697.
148. Daub H, Olsen JV, Bairlein M, et al,. Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell 2008; 31: 438 - 448.
149. Xia Q, Cheng D, Duong DM, et al,. Phosphoproteomic analysis of human brain by calcium phosphate precipitation and mass spectrometry. J Proteome Res 2008; 7: 2845 - 2851.
150. Brill LM, Xiong W, Lee KB, et al,. Phosphoproteomic analysis of human embryonic stem cells. Cell Stem Cell 2009; 5: 204 - 213.
151. Yanai A, Huang K, Kang R, et al,. Palmitoylation of huntingtin by HIP14 is essential for its trafficking and function. Nat Neurosci 2006; 9: 824 - 831.
152. Li H, Xing X, Ding G, et al,. SysPTM: A systematic resource for proteomic research on post-translational modifications. Mol Cell Proteomics 2009; 8: 1839 - 1849.